Psychedelics – News and Features

To learn more about the FDA's pending decision on MDMA-assisted therapy for PTSD, Technology Networks interviewed Dr. Sam Clark, CEO of Terran Biosciences, who leads one of the industry’s largest psychedelic development programs.

In preclinical experiments, researchers optimized a targeted drug delivery method where nanocarriers release their cargo at exactly the desired location.

Interest in a potentially harmful "magic mushroom" is skyrocketing. Amanita muscaria is being marketed as having similar health benefits to psilocybin, despite being completely different.

The first participant in a new psychedelic study has received a dose of a synthetic formulation of 5-MeO-DMT. The study is set to evaluate its neurophysiological effects on the human brain and perceived “mystical experiences.”

Researchers at the University of Colorado Anschutz Medical Campus have established a new framework for understanding how classic antidepressants work in treating major depressive disorder (MDD).

A key advisory panel to the US FDA has voted that midomafetamine (MDMA) is not effective nor risk-free for treating PTSD.

A new study shows how psilocybin initiates hyperconnectivity in the brain, causing feelings of "oceanic boundlessness", providing insights into its potential use to treat psychiatric disorders.

New research addresses a gap in understanding how ketamine’s impact on individual neurons leads to pervasive and profound changes in brain network function.

Some small clinical trials have shown that psilocybin, the active ingredient in magic mushrooms, may be a potential treatment for anorexia nervosa. The condition is characterised by cognitive inflexibility.

Researchers have shed light on how some psychedelic drugs – which show promise in patients with neuropsychiatric disorders such as depression and anxiety – bind to and activate serotonin receptors.